Ferroquine - Sanofi
Alternative Names: SR-97193; SSR-97193Latest Information Update: 02 Oct 2021
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Aminoquinolines; Antimalarials; Ferrous compounds; Small molecules
- Mechanism of Action Hemozoin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 23 Jul 2018 Discontinued - Phase-II for Malaria (In children) in Africa (PO)
- 23 Jul 2018 Discontinued - Phase-II for Malaria in Africa (PO)
- 23 Jul 2018 Discontinued - Phase-II for Malaria in France (PO)